Antibodies against cdcp1 for the treatment and detection of cancer

Abstract

The disclosure is related to antibodies and antibody fragments that specifically bind the CUB domain-containing protein 1 (CDCP1) and their methods and uses in treating and detecting cancers.

1 - 22 . (canceled) 
     
     
         23 . A method for assessing CUB domain-containing protein 1 (CDCP1) expression, comprising:
 (a) administering a radioisotope-labeled antibody or antibody fragment that specifically binds the CDCP1 ectodomain to a subject having pancreatic cancer; and   (b) visualizing binding of the antibody or antibody fragment to cells of the subject to assess CDC1 expression, wherein   the radioisotope is a positron-emitter, and   the antibody or antibody fragment comprises light chain CDRs of SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:20, and heavy chain CDRs of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.   
     
     
         24 . The method of  claim 23 , wherein the antibody or antibody fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), and the VH comprises the amino acid sequence having at least 95% sequence identity to SEQ ID NO:57, and the VL comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:58. 
     
     
         25 . The method of  claim 23 , wherein the antibody or antibody fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), and the VH comprises the amino acid sequence of SEQ ID NO:57, and the VL comprises the amino acid sequence of SEQ ID NO:58. 
     
     
         26 . The method of  claim 23 , wherein the positron-emitter is selected from the group consisting of  68 Ga,  18 F,  64 Cu,  86 Y,  76  Br,  89 Zr, and  124 I. 
     
     
         27 . The method of  claim 26 , wherein the positron-emitter is  89 Zr. 
     
     
         28 . The method of  claim 26 , wherein visualizing comprises use of positron emission tomography (PET). 
     
     
         29 . The method of  claim 23 , wherein the pancreatic cancer is pancreatic adenocarcinoma. 
     
     
         30 . The method of  claim 29 , wherein the pancreatic adenocarcinoma is a pancreatic ductal adenocarcinoma. 
     
     
         31 . A radioisotope-labeled antibody or antibody fragment that specifically binds CUB domain-containing protein 1 (CDCP1) ectodomain and comprises light chain CDRs of SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:20, and heavy chain CDRs of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, wherein the radioisotope is a positron-emitter. 
     
     
         32 . The antibody or antibody fragment of  claim 31 , wherein the antibody or antibody fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), and the VH comprises the amino acid sequence having at least 95% sequence identity to SEQ ID NO:57, and the VL comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:58. 
     
     
         33 . The antibody or antibody fragment of  claim 31 , wherein the antibody or antibody fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), and the VH comprises the amino acid sequence of SEQ ID NO:57, and the VL comprises the amino acid sequence of SEQ ID NO:58. 
     
     
         34 . The antibody or antibody fragment of  claim 31 , wherein the positron-emitter is selected from the group consisting of  68 Ga,  18 F,  64 Cu,  86 Y,  76 Br,  89 Zr, and  124 I. 
     
     
         35 . The antibody or antibody fragment of  claim 34 , wherein the positron-emitter is  89 Zr.